Dr Reddy’s enters anti-vertigo segment with acquisition of Stugeron from Johnson & Johnson

Core Insights - Dr. Reddy's Laboratories has completed a definitive transaction with Johnson & Johnson to acquire Stugeron Forte and Stugeron Plus across 18 markets in the APAC and EMEA regions, with India and Vietnam as key markets [1][5] - The acquisition allows Dr. Reddy's to strengthen its position in the anti-vertigo market, where Stugeron already holds a leading position in India [2][4] - The integration of the Stugeron brand and its portfolio will be managed gradually to ensure a smooth transition [3] Strategic Implications - The acquisition is part of Dr. Reddy's strategy to expand its Central Nervous System (CNS) portfolio and enhance its presence in the anti-vertigo therapeutic segment [2][4] - The company aims to leverage its strong market access to extend the reach of Stugeron and its associated products across the targeted markets [5] - Dr. Reddy's has set a goal to improve patient access and aims to reach over 1.5 billion patients by 2030 [5]